CY1114263T1 - Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα - Google Patents
Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημεραInfo
- Publication number
- CY1114263T1 CY1114263T1 CY20131100643T CY131100643T CY1114263T1 CY 1114263 T1 CY1114263 T1 CY 1114263T1 CY 20131100643 T CY20131100643 T CY 20131100643T CY 131100643 T CY131100643 T CY 131100643T CY 1114263 T1 CY1114263 T1 CY 1114263T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- hours
- pramipexole
- absorption
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Μια χορηγούμενη από το στόμα φαρμακευτική σύνθεση η οποία περιλαμβάνει μια θεραπευτικά αποτελεσματική ποσότητα πραμιπεξόλης ή ένα φαρμακευτικά αποδεκτό άλας αυτής και τουλάχιστον ένα φαρμακευτικά αποδεκτό έκδοχο, με την εν λόγω σύνθεση να επιδεικνύει τουλάχιστον ένα από τα: (α) προφίλ αποδέσμευσης στο δοκιμαστικό σωλήνα στο οποίο κατά μέσο όρο δε διαλύεται περισσότερο από 20% πραμιπεξόλης μέσα σε δυο ώρες από την τοποθέτηση της σύνθεσης σε μια πρότυπη δοκιμή διάλυσης· και (β) προφίλ απορρόφησης της πραμιπεξόλης εσωσωματικά μετά τη χορήγηση μιας δόσης σε υγιείς ενήλικες ανθρώπους, στο οποίο ο χρόνος για να επιτευχθεί ένας μέσος όρος 20% απορρόφησης είναι μεγαλύτερος από περίπου 2 ώρες και/ή ο χρόνος για να επιτευχθεί ένας μέσος όρος 40% απορρόφησης είναι μεγαλύτερος από περίπου 4 ώρες. Η σύνθεση είναι χρήσιμη για χορήγηση από το στόμα, όχι περισσότερο από μια φορά την ημέρα, σε ένα άτομο που έχει μια κατάσταση ή διαταραχή για την οποία ενδείκνυται ένας αγωνιστής του υποδοχέα της ντοπαμίνης.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39844702P | 2002-07-25 | 2002-07-25 | |
US39842702P | 2002-07-25 | 2002-07-25 | |
US47951403P | 2003-06-18 | 2003-06-18 | |
EP10174089.2A EP2289514B9 (en) | 2002-07-25 | 2003-07-25 | Pramipexole once daily dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114263T1 true CY1114263T1 (el) | 2016-08-31 |
Family
ID=31192088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100643T CY1114263T1 (el) | 2002-07-25 | 2013-07-26 | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα |
CY20131100969T CY1114566T1 (el) | 2002-07-25 | 2013-11-01 | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100969T CY1114566T1 (el) | 2002-07-25 | 2013-11-01 | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα |
Country Status (40)
Country | Link |
---|---|
US (2) | US8679533B2 (el) |
EP (2) | EP2289514B9 (el) |
JP (1) | JP4607584B2 (el) |
KR (2) | KR101066374B1 (el) |
CN (1) | CN1671381B (el) |
AP (1) | AP2223A (el) |
AR (1) | AR040682A1 (el) |
AU (1) | AU2003256921B2 (el) |
BR (1) | BR0312948A (el) |
CA (1) | CA2493629C (el) |
CU (1) | CU23468B7 (el) |
CY (2) | CY1114263T1 (el) |
DE (1) | DE20321906U1 (el) |
DK (2) | DK1536792T3 (el) |
EA (1) | EA017595B1 (el) |
EC (1) | ECSP055569A (el) |
ES (2) | ES2436745T3 (el) |
GE (1) | GEP20074047B (el) |
HK (1) | HK1078007A1 (el) |
HR (1) | HRP20041234B1 (el) |
IL (1) | IL166076A0 (el) |
IS (1) | IS7613A (el) |
MA (1) | MA27372A1 (el) |
ME (1) | ME00347B (el) |
MX (1) | MXPA05000980A (el) |
MY (1) | MY142204A (el) |
NO (1) | NO20050481L (el) |
NZ (1) | NZ562681A (el) |
OA (1) | OA12889A (el) |
PA (1) | PA8578501A1 (el) |
PE (1) | PE20040134A1 (el) |
PL (1) | PL375444A1 (el) |
PT (2) | PT1536792E (el) |
RS (1) | RS52764B (el) |
SG (1) | SG177011A1 (el) |
SI (2) | SI2289514T1 (el) |
TW (1) | TWI351955B (el) |
UY (1) | UY27913A1 (el) |
WO (1) | WO2004010999A1 (el) |
ZA (1) | ZA200500015B (el) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US7365086B2 (en) * | 2003-07-25 | 2008-04-29 | Synthon Ip Inc. | Pramipexole acid addition salts |
EP2431026A1 (en) * | 2004-08-13 | 2012-03-21 | Boehringer Ingelheim International GmbH | Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
BRPI0513846A (pt) * | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo |
CN101031322A (zh) * | 2004-10-01 | 2007-09-05 | 日本脏器制药株式会社 | 固体药物制剂 |
WO2006046256A1 (en) * | 2004-10-27 | 2006-05-04 | Alembic Limited | Extended release formulation of pramipexole dihydrochloride |
WO2007090882A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
US20090098202A1 (en) * | 2006-02-10 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Extended Release Formulation |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
US8017598B2 (en) * | 2006-05-16 | 2011-09-13 | Knopp Neurosciences, Inc. | Compositions of R(+) and S(−) pramipexole and methods of using the same |
US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
US10716798B2 (en) | 2007-02-21 | 2020-07-21 | The Regents Of The University Of Michigan | Compositions and methods for tranquilizing heart muscle |
US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
WO2008145252A1 (en) * | 2007-05-25 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation comprising pramipexole |
WO2008150741A1 (en) * | 2007-06-04 | 2008-12-11 | Drugtech Corporation | Controlled release dopamine agonist compositions |
WO2009152041A2 (en) * | 2008-06-09 | 2009-12-17 | Supernus Pharmaceuticals, Inc. | Controlled release formulations of pramipexole |
CN102186350A (zh) | 2008-08-19 | 2011-09-14 | 诺普神经科学股份有限公司 | 使用(r)-普拉克索的组合物与方法 |
US20120021057A1 (en) * | 2009-04-09 | 2012-01-26 | Purdue Pharma | Once-daily oral ir/cr pramipexole formulation |
WO2011002891A1 (en) * | 2009-07-02 | 2011-01-06 | Supernus Pharmaceuticals, Inc. | A method of treatment of a neurological disorder |
WO2011037976A2 (en) * | 2009-09-22 | 2011-03-31 | Dr. Reddy's Laboratories Limited | Pramipexole pharmaceutical formulations |
EP2525786A2 (en) * | 2010-01-18 | 2012-11-28 | Synthon BV | Pramipexole extended release tablets |
TR201001862A1 (tr) * | 2010-03-11 | 2011-10-21 | Sanovel �La� San.Ve T�C.A.�. | Kontrollü salım gerçekleştiren pramipeksol formülasyonları. |
WO2011128914A2 (en) | 2010-04-15 | 2011-10-20 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of pramipexole |
AU2011256928A1 (en) | 2010-05-24 | 2012-12-20 | Lupin Limited | Extended release formulation of pramipexole |
CN102670550A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 盐酸普拉克索渗透泵型控释片 |
WO2013034173A1 (en) | 2011-09-06 | 2013-03-14 | Synthon Bv | Pramipexole extended release tablets |
CN102406626B (zh) * | 2011-12-02 | 2013-08-28 | 深圳海王药业有限公司 | 盐酸普拉克索缓释片剂及其制备方法 |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP2732812A1 (de) | 2012-11-15 | 2014-05-21 | Aristo Pharma GmbH | Pramipexol-Retardtablettenformulierung |
CN103435571B (zh) * | 2012-11-22 | 2015-12-09 | 北京三泉医药技术有限公司 | 四氢苯并噻唑衍生物及其制备方法 |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
BR112016000627B1 (pt) | 2013-07-12 | 2022-02-08 | Knopp Biosciences Llc | Uso de dexpramipexol ou um sal farmaceuticamente aceitável do mesmo |
ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
HUE055850T2 (hu) | 2013-08-13 | 2022-01-28 | Knopp Biosciences Llc | Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére |
CN104606162B (zh) * | 2015-01-07 | 2017-03-29 | 海南康虹医药科技开发有限公司 | 一种盐酸普拉克索缓释制剂及其制备方法 |
CN104784155B (zh) * | 2015-05-15 | 2018-02-23 | 中国药科大学 | 一种盐酸普拉克索组合微丸胶囊及其制备方法 |
CN105030721B (zh) * | 2015-08-30 | 2018-05-04 | 南京康川济医药科技有限公司 | 一种含有盐酸普拉克索的口服固体组合物 |
CN114796163A (zh) * | 2016-10-07 | 2022-07-29 | 全崴生技股份有限公司 | 普拉克索经皮贴片***与用法 |
EP3559320A1 (de) * | 2016-12-21 | 2019-10-30 | HSO Herbert Schmidt GmbH & Co. KG | Beizlösung zum beizen von kunststoffen |
MX2019012594A (es) * | 2017-04-24 | 2020-08-03 | Chase Therapeutics Corp | Composiciones y metodo para tratar la depresion. |
CN111212640A (zh) * | 2017-08-17 | 2020-05-29 | 顾自强 | 单胺抗帕金森药物的双羟萘酸盐、其制备方法及其用途 |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887440A (en) | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
BE604564A (el) | 1960-06-06 | |||
US3458622A (en) | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
JPS58403B2 (ja) * | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4167558A (en) | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
SE8003805L (sv) | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
SE8103843L (sv) * | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
DE3572485D1 (en) * | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US4666612A (en) | 1986-03-17 | 1987-05-19 | Kerr-Mcgee Chemical Corporation | Method for recovering a wood preservative from waste sludges |
US4772473A (en) | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
US4709712A (en) * | 1986-10-22 | 1987-12-01 | Dermatalogical Products Of Texas | Polycarboxylic acid polymer gels as protective agents |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4789549A (en) | 1987-03-09 | 1988-12-06 | Warner-Lambert Company | Sustained release dosage forms |
US4859470A (en) | 1988-06-02 | 1989-08-22 | Alza Corporation | Dosage form for delivering diltiazem |
GB8828020D0 (en) * | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5273975A (en) * | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
EP0447168A3 (en) | 1990-03-16 | 1993-01-07 | Yamanouchi Pharmaceutical Co. Ltd. | Long acting granular pharmaceutical composition |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5656296A (en) | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
US5731338A (en) | 1992-07-02 | 1998-03-24 | Oramed, Inc. | Controlled release pilocarpine delivery system |
SK281042B6 (sk) | 1992-09-18 | 2000-11-07 | Yamanouchi Pharmaceutical Co., Ltd | Prípravok hydrogélového typu s ustáleným uvoľňovaním |
DE4241013A1 (de) | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5484608A (en) | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
US5650420A (en) | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
KR100459029B1 (ko) | 1995-12-27 | 2006-03-27 | 얀센 파마슈티카 엔.브이. | 생점착성고체투여형 |
US5846971A (en) | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
JPH1017497A (ja) | 1996-07-02 | 1998-01-20 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
GB9619074D0 (en) | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
EP0998271B3 (en) * | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
EP1009387B1 (en) | 1997-07-02 | 2006-04-12 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
CA2211778A1 (en) | 1997-08-14 | 1999-02-14 | Francois Carriere | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents |
DE69819748T2 (de) * | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
US6624200B2 (en) * | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6248358B1 (en) * | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
SK285068B6 (sk) | 1997-09-29 | 2006-05-04 | Nektar Therapeutics | Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním |
US6197339B1 (en) | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US20020054911A1 (en) | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
GB9802201D0 (en) | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
NZ505807A (en) * | 1998-03-11 | 2003-01-31 | Smithkline Beecham Corp | Controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride; useful for the treatment or prophylaxis of dementia |
CN1301159A (zh) | 1998-05-15 | 2001-06-27 | 法玛西雅厄普约翰美国公司 | 卡麦角林和普拉克索的新用途和组合 |
US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
TW407058B (en) * | 1998-07-17 | 2000-10-01 | Dev Center Biotechnology | Oral cisapride dosage forms with an extended duration |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
EA200401009A1 (ru) * | 1999-03-31 | 2004-12-30 | Янссен Фармацевтика Н.В. | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением |
DE19927688A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
JP2004500331A (ja) | 1999-07-13 | 2004-01-08 | アルファ リサーチ グループ, エルエルシー | パーキンソン病の処置のための組成物および方法 |
GB9923045D0 (en) | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
AU7620600A (en) | 1999-09-30 | 2001-04-30 | General Hospital Corporation, The | Use of pramipexole as a treatment for ***e craving |
MXPA02003976A (es) | 1999-10-19 | 2003-09-25 | Nps Pharma Inc | Formulaciones de liberacion continua para el tratamiento de desordenes mediados por cns. |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2001045705A1 (en) | 1999-12-22 | 2001-06-28 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
CA2332691C (en) | 2000-01-27 | 2007-11-27 | The York Group, Inc. | Death care merchandising system |
PT1255547E (pt) | 2000-02-08 | 2008-11-24 | Euro Celtique Sa | Composições de libertação controlada contendo agonistas e antagonistas opióides |
PE20011074A1 (es) | 2000-02-23 | 2001-10-04 | Upjohn Co | Uso de pramipexol en el tratamiento de trastornos de adiccion |
CN1660435A (zh) * | 2000-02-24 | 2005-08-31 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US6277875B1 (en) | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
CA2418915A1 (en) | 2000-08-08 | 2002-02-14 | Teva Pharmaceutical Industries Ltd. | Stable pergolide mesylate and process for making same |
ES2187249B1 (es) * | 2000-09-18 | 2004-09-16 | Synthon Bv | Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles. |
SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
US7776345B2 (en) | 2001-07-04 | 2010-08-17 | Sun Pharma Advanced Research Company Ltd | Gastric retention controlled drug delivery system |
FR2827872A1 (fr) | 2001-07-30 | 2003-01-31 | Roussy Inst Gustave | Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire |
US20030032661A1 (en) | 2001-08-02 | 2003-02-13 | Boehringer Ingelheim Pharma Kg | Pramipexole as an anticonvulsant |
GB0125088D0 (en) | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
JP2005516020A (ja) * | 2001-12-20 | 2005-06-02 | ファルマシア・コーポレーション | ゼロ次持続放出剤形およびその製造方法 |
WO2003057278A2 (en) | 2002-01-04 | 2003-07-17 | Ivax Research, Inc. | Drug delivery system for sustained delivery of glipizide |
DE60327843D1 (de) | 2002-03-04 | 2009-07-16 | Ipsen Pharma | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid |
US20050245556A1 (en) | 2002-04-05 | 2005-11-03 | Bianca Brogmann | Pharmaceutical preparation containing oxycodone and naloxone |
CA2481739C (en) | 2002-04-15 | 2012-10-02 | Adams Laboratories, Inc. | Sustained release of guaifenesin combination drugs |
US20030215498A1 (en) | 2002-05-17 | 2003-11-20 | Harland Ronald S. | Rapidly disintegrating comressed tablets comprising biologically active compounds |
JP4445853B2 (ja) | 2002-06-10 | 2010-04-07 | ワイス エルエルシー | 新規o−デスメチルベンラファクシンギ酸塩 |
MXPA05000018A (es) | 2002-06-27 | 2005-04-08 | Cilag Ag | Formulaciones de pellas esfericas. |
AU2003281181A1 (en) | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
BR0312876A (pt) | 2002-07-25 | 2005-06-28 | Pharmacia Corp | Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água |
US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
CA2415154C (en) | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
WO2004058228A1 (en) | 2002-12-24 | 2004-07-15 | Lupin Limited | Enteric coated fluoxetine composition |
US20050020589A1 (en) * | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
BRPI0513846A (pt) | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo |
EP2431026A1 (en) * | 2004-08-13 | 2012-03-21 | Boehringer Ingelheim International GmbH | Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
US20090098202A1 (en) * | 2006-02-10 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Extended Release Formulation |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
EP1886665A1 (en) * | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
JP5220746B2 (ja) | 2006-08-25 | 2013-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 制御放出システム及びその製造方法 |
-
2003
- 2003-07-24 MY MYPI20032783A patent/MY142204A/en unknown
- 2003-07-24 US US10/626,275 patent/US8679533B2/en active Active
- 2003-07-24 PE PE2003000736A patent/PE20040134A1/es not_active Application Discontinuation
- 2003-07-24 AR AR20030102667A patent/AR040682A1/es unknown
- 2003-07-24 PA PA20038578501A patent/PA8578501A1/es unknown
- 2003-07-25 GE GEAP8598A patent/GEP20074047B/en unknown
- 2003-07-25 ES ES03771959.8T patent/ES2436745T3/es not_active Expired - Lifetime
- 2003-07-25 WO PCT/US2003/023522 patent/WO2004010999A1/en active Application Filing
- 2003-07-25 BR BR0312948-9A patent/BR0312948A/pt not_active IP Right Cessation
- 2003-07-25 SI SI200332276T patent/SI2289514T1/sl unknown
- 2003-07-25 DK DK03771959.8T patent/DK1536792T3/da active
- 2003-07-25 JP JP2004524936A patent/JP4607584B2/ja not_active Expired - Fee Related
- 2003-07-25 SI SI200332311T patent/SI1536792T1/sl unknown
- 2003-07-25 PT PT37719598T patent/PT1536792E/pt unknown
- 2003-07-25 OA OA1200500017A patent/OA12889A/en unknown
- 2003-07-25 PT PT101740892T patent/PT2289514E/pt unknown
- 2003-07-25 RS RS115104A patent/RS52764B/en unknown
- 2003-07-25 EP EP10174089.2A patent/EP2289514B9/en not_active Expired - Lifetime
- 2003-07-25 KR KR1020077012380A patent/KR101066374B1/ko not_active IP Right Cessation
- 2003-07-25 MX MXPA05000980A patent/MXPA05000980A/es unknown
- 2003-07-25 ME MEP-2008-522A patent/ME00347B/me unknown
- 2003-07-25 DE DE20321906U patent/DE20321906U1/de not_active Expired - Lifetime
- 2003-07-25 AP AP2005003206A patent/AP2223A/xx active
- 2003-07-25 EA EA200500080A patent/EA017595B1/ru not_active IP Right Cessation
- 2003-07-25 CN CN038178311A patent/CN1671381B/zh not_active Expired - Fee Related
- 2003-07-25 NZ NZ562681A patent/NZ562681A/en not_active IP Right Cessation
- 2003-07-25 EP EP03771959.8A patent/EP1536792B1/en not_active Expired - Lifetime
- 2003-07-25 AU AU2003256921A patent/AU2003256921B2/en not_active Expired
- 2003-07-25 PL PL03375444A patent/PL375444A1/xx unknown
- 2003-07-25 ES ES10174089T patent/ES2421787T3/es not_active Expired - Lifetime
- 2003-07-25 TW TW092120436A patent/TWI351955B/zh not_active IP Right Cessation
- 2003-07-25 DK DK10174089.2T patent/DK2289514T5/da active
- 2003-07-25 SG SG2008086357A patent/SG177011A1/en unknown
- 2003-07-25 CA CA2493629A patent/CA2493629C/en not_active Expired - Fee Related
- 2003-07-25 KR KR1020057001294A patent/KR20050025654A/ko not_active Application Discontinuation
- 2003-07-31 UY UY27913A patent/UY27913A1/es not_active Application Discontinuation
-
2004
- 2004-12-23 IS IS7613A patent/IS7613A/is unknown
- 2004-12-30 HR HRP20041234AA patent/HRP20041234B1/hr not_active IP Right Cessation
- 2004-12-30 IL IL16607604A patent/IL166076A0/xx unknown
-
2005
- 2005-01-03 ZA ZA200500015A patent/ZA200500015B/en unknown
- 2005-01-24 EC EC2005005569A patent/ECSP055569A/es unknown
- 2005-01-25 CU CU20050019A patent/CU23468B7/es unknown
- 2005-01-25 MA MA28067A patent/MA27372A1/fr unknown
- 2005-01-27 NO NO20050481A patent/NO20050481L/no not_active Application Discontinuation
- 2005-11-09 HK HK05109990.6A patent/HK1078007A1/xx not_active IP Right Cessation
-
2013
- 2013-07-26 CY CY20131100643T patent/CY1114263T1/el unknown
- 2013-11-01 CY CY20131100969T patent/CY1114566T1/el unknown
-
2014
- 2014-01-28 US US14/165,743 patent/US20140141079A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114263T1 (el) | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα | |
CY1109270T1 (el) | Ανθεκτικα στην παραβιαση στοματικα σκευασματα οπιουχων αγωνιστων | |
NO20052019L (no) | Blanding for a inhibere sekresjon av magesyre | |
AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
NO20051854L (no) | Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse. | |
CY1106727T1 (el) | Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων | |
CY1117470T1 (el) | Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση | |
UY30537A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
NO20100041L (no) | Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer | |
DE69831869D1 (de) | Verbesserte verabreichungstechnik für multiple medikamentengaben | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
CY1105120T1 (el) | Η αντιμετωπιση αναπνευστικων νοσων | |
CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
ES2091877T3 (es) | Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia. | |
ES2181417T3 (es) | Formulacion de capsulas o tabletas de efavirenz de disolucion rapida usando super-desintegrantes. | |
ES2579857T3 (es) | Composiciones de plasma rico en plaquetas | |
AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
RU98102392A (ru) | Производные дифенилметиленпиперидина | |
AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
ES2524369T3 (es) | Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento | |
CY1109939T1 (el) | Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου | |
AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
ECSP11010999A (es) | Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina |